[{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Affamed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"TRHR","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kissei Pharmaceutical \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ CG Oncology"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Kissei Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 01, 2025

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Rigel Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 21, 2025

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : JW Pharmaceutical Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Tai Tien Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 23, 2022

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Rigel Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2022

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Rigel Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 21, 2021

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Rigel Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Inmagene will be responsible for the development and commercialization rights in China for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 05, 2021

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inmagene Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : JW Pharma will be responsible for the development and commercialization rights in Korea for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.

                          Product Name : Tavalisse

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 28, 2021

                          Lead Product(s) : Fostamatinib Disodium Hexahydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : JW Pharmaceutical Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : CG0070, a oncolytic immunotherapy in which adenovirus is genetically modified to enhance bladder tumor cells selectivity and anticancer activity, and is injected into the bladder using a urinary tract catheter.

                          Product Name : CG0070

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          March 24, 2021

                          Lead Product(s) : Cretostimogene Grenadenorepvec

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : CG Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.

                          Product Name : AJM300

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2021

                          Lead Product(s) : Carotegrast Methyl

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : EA Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank